Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Cited by (1,023)

Items 101–200 of 1,023

1. A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
   Takaaki Sasaki, Jussi Pekka Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher S. Lathan, J. Paul Marcoux, Jinyan Du, Katsuhiro Okuda et al. · 2011 · Cancer Research
2. Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
   Takayuki Kosaka, Yasushi Yatabe, Hideki Endoh, Kimihide Yoshida, Toyoaki Hida, Masahiro Tsuboi, Hirohito Tada, Hiroyuki Kuwano, Tetsuya Mitsudomi · 2006 · Clinical Cancer Research
3. Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
   Jackman, David M., Yeap, Beow Y., Sequist, Lecia V., Lindeman, Neal, Holmes, Alison J., Joshi, Victoria A., Bell, Daphne W., Huberman, Mark S., Halmos, Balazs, Rabin, Michael S. et al. · 2006 · Clinical Cancer Research
4. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
   Niederst, Matthew J., Hu, Haichuan, Mulvey, Hillary E., Lockerman, Elizabeth L., Garcia, Angel R., Piotrowska, Zofia, Sequist, Lecia V., Engelman, Jeffrey A. · 2015 · Clinical Cancer Research
5. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
   Arcila, Maria E., Oxnard, Geoffrey R., Nafa, Khedoudja, Riely, Gregory J., Solomon, Stephen B., Zakowski, Maureen F., Kris, Mark G., Pao, William, Miller, Vincent A., Ladanyi, Marc · 2011 · Clinical Cancer Research
6. Overcoming therapy resistance in EGFR-mutant lung cancer
   Passaro, Antonio, Jänne, Pasi A., Mok, Tony, Peters, Solange · 2021 · Nature Cancer
7. Resistance to targeted therapy in renal-cell carcinoma
   Brian I. Rini, Michael B. Atkins · 2009 · The Lancet Oncology
8. Biomarker development in the precision medicine era: lung cancer as a case study
   Ashley J. Vargas, Curtis C. Harris · 2016 · Nature reviews. Cancer
9. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
   Wheeler, D L, Huang, S, Kruser, T J, Nechrebecki, M M, Armstrong, E A, Benavente, S, Gondi, V, Hsu, K-T, Harari, P M · 2008 · Oncogene
10. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
    Todd A. Carter, Lisa M. Wodicka, Neil P. Shah, Anne Marie Velasco, Miles A. Fabian, Daniel K. Treiber, Zdravko V. Milanov, Corey E. Atteridge, William Biggs, Philip T. Edeen et al. · 2005 · Proceedings of the National Academy of Sciences
11. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
    Ryohei Katayama, Tahsin M. Khan, Cyril H. Benes, Eugene Lifshits, Hiromichi Ebi, Victor M. Rivera, William C. Shakespeare, Anthony John Iafrate, Jeffrey A. Engelman, Alice Tsang Shaw · 2011 · Proceedings of the National Academy of Sciences
12. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
    Yewale, Chetan, Baradia, Dipesh, Vhora, Imran, Patil, Sushilkumar, Misra, Ambikanandan · 2013 · Biomaterials
13. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients
    Yang, Zhe, Yang, Nong, Ou, Qiuxiang, Xiang, Yi, Jiang, Tao, Wu, Xue, Bao, Hua, Tong, Xiaoling, Wang, Xiaonan, Shao, Yang W. et al. · 2018 · Clinical Cancer Research
14. Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
    Misale, Sandra, Di Nicolantonio, Federica, Sartore-Bianchi, Andrea, Siena, Salvatore, Bardelli, Alberto · 2014 · Cancer Discovery
15. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K.H., Lu, S. et al. · 2017 · Annals of Oncology
16. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Daphne W. Bell, Ira Gore, Ross A. Okimoto, Nadia Godin-Heymann, Raffaella Sordella, Roseann Mulloy, Sreenath V. Sharma, Brian W. Brannigan, Gayatry Mohapatra, Jeff Settleman et al. · 2005 · Nature Genetics
17. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Juliann Chmielecki, Jasmine Foo, Geoffrey R. Oxnard, Katherine E. Hutchinson, Kadoaki Ohashi, Romel Somwar, Lu Wang, Katherine R. Amato, Maria E. Arcila, Martin L. Sos et al. · 2011 · Science Translational Medicine
18. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
    Marta Guix, Anthony C. Faber, Shizhen Emily Wang, Maria Graciela Olivares, Youngchul Song, Sherman Qu, Cammie Rinehart, Brenda Seidel, Douglas Yee, Carlos L. Arteaga et al. · 2008 · Journal of Clinical Investigation
19. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression
    Suhaida A. Selamat, Brian S. I. Chung, Luc Girard, Wei Zhang, Ying Zhang, Mihaela Campan, Kimberly D. Siegmund, Michael N. Koss, Jeffrey A. Hagen, Wan L. Lam et al. · 2012 · Genome Research
20. Circumventing cancer drug resistance in the era of personalized medicine
    Garraway, Levi A., Jänne, Pasi A. · 2012 · Cancer Discovery
21. Glioblastoma: From Molecular Pathology to Targeted Treatment
    Timothy Francis Cloughesy, Webster K. Cavenee, Paul S. Mischel · 2011 · Annual Review of Pathology Mechanisms of Disease
22. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
    Inoue, Akira, Suzuki, Takuji, Fukuhara, Tatsuro, Maemondo, Makoto, Kimura, Yuichiro, Morikawa, Naoto, Watanabe, Hiroshi, Saijo, Yasuo, Nukiwa, Toshihiro · 2006 · Journal of Clinical Oncology
23. Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
    Clara O. Montagut, Sreenath V. Sharma, Toshi Shioda, Ultan McDermott, Matthew J. Ulman, Lindsey E. Ulkus, Dora C. Dias-Santagata, Hannah Stubbs, Diana Wing Lee, Anurag Singh et al. · 2008 · Cancer Research
24. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
    Jake June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong‐Wan Kim, Dae Seog Heo et al. · 2017 · Journal of Clinical Oncology
25. Signaling networks assembled by oncogenic EGFR and c-Met
    Ailan Guo, Judit Villén, Jon M. Kornhauser, Kimberly A. Lee, Matthew P. Stokes, Klarisa Rikova, Anthony P. Possemato, Julie Nardone, Gregory Innocenti, Randall K. Wetzel et al. · 2008 · Proceedings of the National Academy of Sciences
26. Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
    Su, Kang-Yi, Chen, Hsuan-Yu, Li, Ker-Chau, Kuo, Min-Liang, Yang, James Chih-Hsin, Chan, Wing-Kai, Ho, Bing-Ching, Chang, Gee-Chen, Shih, Jin-Yuan, Yu, Sung-Liang et al. · 2012 · Journal of Clinical Oncology
27. BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
    Daniel Botelho Costa, Balázs Halmos, Amit Kumar, Susan Schumer, Mark S. Huberman, Titus J. Boggon, Daniel Geoffrey Tenen, Susumu S. Kobayashi · 2007 · PLoS Medicine
28. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
    Yauch, Robert L., Januario, Thomas, Eberhard, David A., Cavet, Guy, Zhu, Wenjing, Fu, Ling, Pham, Thinh Q., Soriano, Robert, Stinson, Jeremy, Seshagiri, Somasekar et al. · 2005 · Clinical Cancer Research
29. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL
    Liu, Li, Greger, James, Shi, Hong, Liu, Yuan, Greshock, Joel, Annan, Roland, Halsey, Wendy, Sathe, Ganesh M., Martin, Anne-Marie, Gilmer, Tona M. · 2009 · Cancer Research
30. Intratumor Heterogeneity: Seeing the Wood for the Trees
    Timothy Anthony Yap, Marco Gerlinger, P. Andrew Futreal, Lajos Pusztai, Charles Swanton · 2012 · Science Translational Medicine
31. Non–Small Cell Lung Cancer, Version 6.2015
    Ettinger, David S., Wood, Douglas E., Akerley, Wallace, Bazhenova, Lyudmila A., Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T., Chirieac, Lucian R., D’Amico, Thomas A., Demmy, Todd L. et al. · 2015 · Journal of the National Comprehensive Cancer Network
32. Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
    Peter S. Hammerman, Martin L. Sos, Alex H. Ramos, Chunxiao Xu, Amit Dutt, Wenjun Zhou, Lear E. Brace, Brittany A. Woods, Wenchu Lin, Jianming Zhang et al. · 2011 · Cancer Discovery
33. Targeting Tyrosine Kinases in Cancer: The Second Wave
    Jose M Baselga · 2006 · Science
34. Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors
    Politi, Katerina, Zakowski, Maureen F., Fan, Pang-Dian, Schonfeld, Emily A., Pao, William, Varmus, Harold E. · 2006 · Genes & Development
35. BAY 43-9006 Inhibition of Oncogenic RET Mutants
    Francesca Carlomagno, Suresh Anaganti, Teresa Guida, Giuliana Salvatore, Giancarlo Troncone, Scott M. Wilhelm, Massimo Mattia Santoro · 2006 · JNCI Journal of the National Cancer Institute
36. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
    Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S W, Felip, Enriqueta, Chow, Laura Q M, Camidge, D Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J et al. · 2016 · The Lancet Oncology
37. Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
    Wu, Jenn-Yu, Yu, Chong-Jen, Chang, Yeun-Chung, Yang, Chih-Hsin, Shih, Jin-Yuan, Yang, Pan-Chyr · 2011 · Clinical Cancer Research
38. Diffuse Glioma Heterogeneity and Its Therapeutic Implications
    James Nicholson, Howard Alan Fine · 2021 · Cancer Discovery
39. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
    Ohashi, Kadoaki, Maruvka, Yosef E., Michor, Franziska, Pao, William · 2013 · Journal of Clinical Oncology
40. ALK in Lung Cancer: Past, Present, and Future
    Alice Tsang Shaw, Jeffrey A. Engelman · 2013 · Journal of Clinical Oncology
41. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
    J. A. Engelman, Toru Mukohara, Kreshnik Zejnullahu, Eugene Lifshits, Ana M. Borras, Christopher-Michael Gale, George N. Naumov, Beow Yong Yeap, E. Jarrell, J. Sun et al. · 2006 · Journal of Clinical Investigation
42. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
    Neal Ian Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Đačić, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan‐Sebastian Saldivar, Jeremy Andrew Squire et al. · 2013 · Journal of Molecular Diagnostics
43. Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer
    Michio Inukai, Shinichi Toyooka, Sachio Ito, Hiroaki Asano, Shuji Ichihara, Junichi Soh, Hiroshi Suehisa, Mamoru Ouchida, Keisuke Aoe, Motoi Aoe et al. · 2006 · Cancer Research
44. Impact of a five-dimensional framework on R&D productivity at AstraZeneca
    Paul Morgan, Dean G. Brown, Simon Lennard, Mark J. Anderton, J. Carl Barrett, Ulf G. Eriksson, Mark D. Fidock, Bengt Hamrén, Anthony G. Johnson, Ruth E. March et al. · 2018 · Nature Reviews Drug Discovery
45. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
    Ji, Hongbin, Li, Danan, Chen, Liang, Shimamura, Takeshi, Kobayashi, Susumu, McNamara, Kate, Mahmood, Umar, Mitchell, Albert, Sun, Yangping, Al-Hashem, Ruqayyah et al. · 2006 · Cancer Cell
46. Targeting cancer with kinase inhibitors
    Stefan David Gross, Rami Rahal, Nicolas Stransky, Christoph Lengauer, Klaus P. Hoeflich · 2015 · Journal of Clinical Investigation
47. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
    Howard A. Burris · 2013 · Cancer Chemotherapy and Pharmacology
48. Plasma AR and abiraterone-resistant prostate cancer
    Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, Anuradha Jayaram, Nicola Andrea Casiraghi, Daniel Wetterskog, Samanta Salvi, Dino Amadori, Zafeiris Zafeiriou, Pasquale Rescigno et al. · 2015 · Science Translational Medicine
49. Oncogene addiction: setting the stage for molecularly targeted cancer therapy
    Sreenath V. Sharma, Jeffrey E. Settleman · 2007 · Genes & Development
50. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
    Ohashi, Kadoaki, Sequist, Lecia V., Arcila, Maria E., Moran, Teresa, Chmielecki, Juliann, Lin, Ya-Lun, Pan, Yumei, Wang, Lu, de Stanchina, Elisa, Shien, Kazuhiko et al. · 2012 · Proceedings of the National Academy of Sciences
51. The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
    Josep M. Tabernero · 2007 · Molecular Cancer Research
52. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
    Nguyen, Kim-Son H., Kobayashi, Susumu, Costa, Daniel B. · 2009 · Clinical Lung Cancer
53. Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
    Lecia Van Dam Sequist, Benjamin Besse, Thomas James Lynch, Vincent A. Miller, Kwok‐Kin Wong, Barbara Jennifer Gitlitz, Keith D. Eaton, Charles Zacharchuk, Amy Freyman, Christine Powell et al. · 2010 · Journal of Clinical Oncology
54. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    Neal Ian Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Đačić, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan‐Sebastian Saldivar, Jeremy Andrew Squire et al. · 2013 · Archives of Pathology & Laboratory Medicine
55. Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
    Vince D. Cataldo, Don Lynn Gibbons, Roman Perez-Soler, Alfonso Quintás‐Cardama · 2011 · New England Journal of Medicine
56. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
    Neil P. Shah, Brian J. Skaggs, Susan Branford, Timothy P. Hughes, John M. Nicoll, RONALD L. PAQUETTE, Charles L. Sawyers · 2007 · Journal of Clinical Investigation
57. Combine and conquer: challenges for targeted therapy combinations in early phase trials
    Lopez, Juanita S., Banerji, Udai · 2017 · Nature Reviews Clinical Oncology
58. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
    Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Kim, Sang-We, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji et al. · 2015 · The Lancet Oncology
59. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
    James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su, Te‐Chun Hsia, Chun‐Ming Tsai, Sai‐Hong Ignatius Ou, Chong‐Jen Yu, Gee‐Chen Chang, Ching‐Liang Ho, Lecia Van Dam Sequist et al. · 2012 · The Lancet Oncology
60. Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
    Pasi Antero Janne, Jeffrey A. Engelman, Bruce Evan Johnson · 2005 · Journal of Clinical Oncology
61. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
    Mariangela Russo, Giulia Siravegna, Lawrence Scott Blaszkowsky, Giorgio Corti, Giovanni Crisafulli, Leanne G. Ahronian, Benedetta Mussolin, Eunice Lee Kwak, Michela Buscarino, Luca Lazzari et al. · 2015 · Cancer Discovery
62. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
    Bivona, Trever G., Hieronymus, Haley, Parker, Joel, Chang, Kenneth, Taron, Miquel, Rosell, Rafael, Moonsamy, Philicia, Dahlman, Kimberly, Miller, Vincent A., Costa, Carlota et al. · 2011 · Nature
63. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
    Dora C. Dias-Santagata, Sara Akhavanfard, Serena S. David, Kathy Vernovsky, Georgiana Kuhlmann, Susan L. Boisvert, Hannah Stubbs, Ultan McDermott, Jeffrey E. Settleman, Eunice Lee Kwak et al. · 2010 · EMBO Molecular Medicine
64. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
    Satoshi Watanabe, Junta Tanaka, Takeshi Ota, Rie Kondo, Hiroshi Tanaka, Hiroshi Kagamu, Kosuke Ichikawa, Jun Koshio, Junko Baba, Takao Miyabayashi et al. · 2011 · BMC Cancer
65. Anticancer drug resistance: An update and perspective
    Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang · 2021 · Drug Resistance Updates
66. Resistance to BRAF-targeted therapy in melanoma
    Ryan Joseph Sullivan, Keith T. Flaherty · 2013 · European Journal of Cancer
67. Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
    Brent Neil Rexer, Carlos L. Arteaga · 2012 · Critical Reviews™ in Oncogenesis
68. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
    Lucía Regales, Yixuan Gong, Ronglai Shen, Elisa de Stanchina, Igor Vivanco, Aviva J. Goel, Jason A. Koutcher, Maria K. Spassova, Ouathek Ouerfelli, Ingo K. Mellinghoff et al. · 2009 · Journal of Clinical Investigation
69. Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis
    Noriko Motoi, János Szőke, Gregory J. Riely, Venkatraman Seshan, Mark G. Kris, Valerie W. Rusch, William L. Gerald, William David Travis · 2008 · The American Journal of Surgical Pathology
70. Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
    Priya Koppikar, Neha Bhagwat, Outi Kilpivaara, Taghi Manshouri, Mazhar Adli, Todd Hricik, Fan Liu, Lindsay M. Saunders, Ann Mullally, Omar Ibrahim Abdel-Wahab et al. · 2012 · Nature
71. Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
    Amit Dutt, Alex H. Ramos, Peter S. Hammerman, Craig H. Mermel, Jeonghee Cho, Tanaz Sharifnia, Ajit G. Chande, Kumiko Tanaka, Nicolas Stransky, Heidi E. Greulich et al. · 2011 · PLoS ONE
72. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Katherine Hastings, Helena Alexandra Yu, Wen Wei, Francisco Sánchez-Vega, Michelle DeVeaux, Jungmin Choi, Hira A. Rizvi, Aaron Elliott Lisberg, Anna Truini, Christine Lydon et al. · 2019 · Annals of Oncology
73. EGFR signaling pathway as therapeutic target in human cancers
    Elena Levantini, Giorgia Maroni, Marzia Del Re, Daniel Geoffrey Tenen · 2022 · Seminars in Cancer Biology
74. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
    Marc Ladanyi, William J. Pao · 2008 · Modern Pathology
75. Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations
    Janjigian, Yelena Y., Smit, Egbert F., Groen, Harry J.M., Horn, Leora, Gettinger, Scott, Camidge, D. Ross, Riely, Gregory J., Wang, Bushi, Fu, Yali, Chand, Vikram K. et al. · 2014 · Cancer Discovery
76. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
    Roman Kurt Thomas, Elizabeth Nickerson, Jan Fredrik Simons, Pasi Antero Janne, Torstein Tengs, Yuki Yuza, Levi A. Garraway, Thomas LaFramboise, Jeffrey C. Lee, Kinjal Shah et al. · 2006 · Nature Medicine
77. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
    Gregory J. Riely, Katerina A. Politi, Vincent A. Miller, William J. Pao · 2006 · Clinical Cancer Research
78. BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
    Corcoran, Ryan B., Dias-Santagata, Dora, Bergethon, Kristin, Iafrate, A. John, Settleman, Jeffrey, Engelman, Jeffrey A. · 2010 · Science Signaling
79. Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
    Shan Zhao, Ravi Iyengar · 2011 · The Annual Review of Pharmacology and Toxicology
80. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
    NISC Comparative Sequencing Program, Prickett, Todd D, Agrawal, Neena S, Wei, Xiaomu, Yates, Kristin E, Lin, Jimmy C, Wunderlich, John R, Cronin, Julia C, Cruz, Pedro, Rosenberg, Steven A et al. · 2009 · Nature Genetics
81. New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
    Geoffrey R. Oxnard, Maria E. Arcila, Juliann Chmielecki, Marc Ladanyi, Vincent A. Miller, William J. Pao · 2011 · Clinical Cancer Research
82. Ten things you should know about protein kinases: IUPHAR R eview 14
    Doriano Fabbro, Sandra W. Cowan‐Jacob, Henrik Möbitz · 2015 · British Journal of Pharmacology
83. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
    Ciric To, Jaebong Jang, Ting Chen, Eunyoung Park, Mierzhati Mushajiang, Dries J.H. De Clercq, Man Xu, Stephen Wang, Michael D. Cameron, David E. Heppner et al. · 2019 · Cancer Discovery
84. Non–Small Cell Lung Cancer
    David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas Anthony D’Amico, Todd L. Demmy, Apar Kishor Ganti, Ramaswamy Govindan et al. · 2012 · Journal of the National Comprehensive Cancer Network
85. Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
    Yap, Timothy A., Vidal, Laura, Adam, Jan, Stephens, Peter, Spicer, James, Shaw, Heather, Ang, Jooern, Temple, Graham, Bell, Susan, Shahidi, Mehdi et al. · 2010 · Journal of Clinical Oncology
86. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., Lassman, A. B. · 2011 · Neuro-Oncology
87. Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
    Sundaresan, Tilak K., Sequist, Lecia V., Heymach, John V., Riely, Gregory J., Jänne, Pasi A., Koch, Walter H., Sullivan, James P., Fox, Douglas B., Maher, Robert, Muzikansky, Alona et al. · 2016 · Clinical Cancer Research
88. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
    George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjørn Straume, Lars A. Akslen, Eugene Lifshits, Lauren A. Byers, Li Xu, Hua-Kang Wu et al. · 2009 · Clinical Cancer Research
89. Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
    Justin F. Gainor, Alice Tsang Shaw · 2013 · Journal of Clinical Oncology
90. The epidermal growth factor receptor: from development to tumorigenesis
    Maria Chiara Sibilia, Renate Kroismayr, Beate M. Lichtenberger, Anuradha Natarajan, Manfred Hecking, Martin Holcmann · 2007 · Differentiation
91. Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
    Yihua Sun, Yan Ren, Zhaoyuan Fang, Chenguang Li, Rong Fang, Bin Gao, Xiangkun Han, Weidong Tian, William J. Pao, Haiquan Chen et al. · 2010 · Journal of Clinical Oncology
92. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
    Recondo, Gonzalo, Facchinetti, Francesco, Olaussen, Ken A., Besse, Benjamin, Friboulet, Luc · 2018 · Nature Reviews Clinical Oncology
93. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer
    Samir Hanash, Christina S. Baik, Olli Kallioniemi · 2011 · Nature Reviews Clinical Oncology
94. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
    Ping Song, Lucia Ruojia Wu, Yan Helen Yan, Jinny Xuemeng Zhang, Tianqing Chu, Lawrence N. Kwong, Abhijit A. Patel, David Yu Zhang · 2022 · Nature Biomedical Engineering
95. Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer
    Hideharu Kimura, Kazuo Kasahara, Makoto Kawaishi, Hideo Kunitoh, Tomohide Tamura, Brian R. Holloway, Kazuto Nishio · 2006 · Clinical Cancer Research
96. Refining the treatment of NSCLC according to histological and molecular subtypes
    Anish Thomas, Stephen V. Liu, Deepa Suresh Subramaniam, Giuseppe Giaccone · 2015 · Nature Reviews Clinical Oncology
97. Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
    Yixuan Gong, Romel Somwar, Katerina A. Politi, Marissa N. Balak, Juliann Chmielecki, Xuejun Jiang, William J. Pao · 2007 · PLoS Medicine
98. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
    Faber, Anthony C., Li, Danan, Song, YoungChul, Liang, Mei-Chih, Yeap, Beow Y., Bronson, Roderick T., Lifshits, Eugene, Chen, Zhao, Maira, Sauveur-Michel, García-Echeverría, Carlos et al. · 2009 · Proceedings of the National Academy of Sciences
99. Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
    Toru Mukohara, Jeffrey A. Engelman, Nasser H. Hanna, Beow Yong Yeap, Susumu S. Kobayashi, Neal Ian Lindeman, Balázs Halmos, Joseph Pearlberg, Zenta Tsuchihashi, Lewis C. Cantley et al. · 2005 · JNCI Journal of the National Cancer Institute
100. Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
     Taniguchi, Kazuya, Uchida, Junji, Nishino, Kazumi, Kumagai, Toru, Okuyama, Takako, Okami, Jiro, Higashiyama, Masahiko, Kodama, Ken, Imamura, Fumio, Kato, Kikuya · 2011 · Clinical Cancer Research